30 Day Trial

Anika Therapeutics 2Q18 Orthobiologics Revenue +7% YoY

Share:

Anika Therapeutics posted 2Q18 orthobiologic revenue of US $26.2MM, +7.0% vs. 2Q17 and 1H18 revenue of $45.7MM, +2.2% vs. 1H17.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.